An important antioxidant involved in energy production.
Each tablet provides a full 300mg of Alpha Lipoic Acid (ALA), making this one of the most potent products on the market. Alpha Lipoic Acid is a vitamin-like substance and there has been considerable research and interest in the use of ALA. Our bodies are able to make ALA although a dietary source is still important, and it is found in almost all foods, especially in kidney, liver, spinach and broccoli.
These taste free coated tablets are made in the UK in a factory working to pharmaceutical GMP standards.
ALA treatment showed small, yet significant short-term weight loss compared to placebo.
Diabetics: Please consult a doctor prior to taking alpha lipoic acid as it may enhance insulin activity.
See presentation section for ingredients listed in bold.
The following list of allergens are excluded: Wheat, Barley, Soya, Eggs, Milk (and milk products), Lactose, Nuts, Sulphites, Celery, Fish, Shellfish, Yeast and Gluten containing ingredients.
This product is not recommended for pregnant or lactating women. Those suffering from diabetes should consult a doctor prior to taking alpha lipoic acid as it may enhance insulin activity.
To be stored in a cool dry place and protected from light.
A pale green oval coated tablet.
Each tablet delivers:
|Alpha Lipoic Acid||300mg|
Calcium Carbonate, Cellulose, Tablet Coating (Hydroxypropyl Methylcellulose, Glycerin), Silicon Dioxide, Stearic Acid, Magnesium Stearate.
Less than 1 hour.
Suitable for vegetarians.
“When looking at data from clinical trials, ALA has revealed to be efficient in particular diseases and conditions, including diabetic neuropathy, obesity, schizophrenia, MS, abnormalities in pregnancy and organ transplantation, with no or minor adverse effects. ALA seems to be also a promising agent to improve quality of life, as well as neuropathic symptoms and even to reduce the use of rescue drugs, which are commonly used by patients with diabetic neuropathy. Moreover, it has the potential to improve lipid metabolism and promote weight reduction in obese patients, besides to alleviate CNS-related diseases (Schizophrenia and MS) symptoms. ALA may also decrease body mass gain caused by the application of prescribed antipsychotic agents, as well as some metabolic risk factors in patients with schizophrenia. In patients with MS, ALA has some positive outcomes, especially in the enhancement of walking and balance disabilities, while decreasing the levels of some proinflammatory factors related to MS progression. Therefore, the clinical trials assessing the ALA effects show its ability to alleviate some symptoms, commonly found in CNS diseases, with highly promising results. In the case of threatened pregnancies, ALA demonstrated beneficial effects on the enhancement of sub-chronic hematoma symptoms, as well as positive results in miscarriage prevention, with no adverse effects. ALA is also effective in organ transplantation patients by reducing the levels of inflammatory factors and exerting protective effects against hypoxia and oxidative stress, whereas in case of neurotoxicity caused by cytotoxic chemotherapy medication ALA did not represent a protective function. Taken all together, ALA may be classified as one of the candidate molecules for prevention or slowing down some conditions associated with several diseases’ progression. ”
Source: Salehi B, Berkay Yılmaz Y, Antika G, et al. Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules. 2019;9(8):356. Published 2019 Aug 9. doi:10.3390/biom9080356